With experience working at startup companies over the years, we know it’s vital to be strategic about the opportunities you pursue. Our unique blend of expertise and strategy help us to identify the best opportunities for your products and ultimately achieve the results you need.
Evaluate potential market and customer segments; evaluate the competitive landscape, and identify ideal opportunities for your technology
Conduct in depth stakeholder research, assess potential needs, and identify customer segments that will value your technology
Assess potential indications, develop use cases, and produce competitive positioning for your technology and build a development plan to efficiently pursue the opportunity
Plan for success by developing a comprehensive strategy for your products, capabilities, financing, and partnering
Develop company and product positioning and create marketing materials to support partnering and fundraising efforts
See Case Studies
Start-Up Biotech Company Secures Investment by Utilizing Market Assessment
Situation A seed stage biotech company focused on developing biosimilar molecules for the global market needed to prioritize potential biosimilar molecules and global markets to refine forecasts and support Series A fundraising efforts. 3elms was tasked to evaluate the market attractiveness of three potential biosimilar programs in the US, EU5, and Asia.
Solution We developed summaries of health care systems, which included insurance schemes, pharmacy coverage, and access to healthcare resources in fifteen countries. In addition, 3elms evaluated the market size and competitive landscape for potential indications and mapped regulatory requirements and timelines for each indication/ biosimilar. We also identified potential requirements and barriers to entry for each market (e.g., partner with local country, establish in-country manufacturing). Lastly, we built high-level forecast estimates for each country, biosimilar, and indication.
Outcome We worked with client leadership to prioritize their biosimilar programs and develop go-to-market plan for major geographies. Using the market and forecast materials developed through our work, our client was able to secure Series A investment.
Situation An early stage company evaluating a novel office-based prostate cancer diagnostic for potential in-licensing and commercialization. They had preliminary human data and as well as a developed testing flow. 3elms was asked to evaluate stakeholder requirements for the test, assess product-market fit, and estimate commercial potential.
Solution We performed an in-depth competitive assessment of in-market and pipeline prostate cancer diagnostics. From there, we developed a perspective on challenges with current approaches and the estimated cost for both the patient and system from low specificity. Finally, we conducted in-depth primary research with urologists and urology office managers to understand patient flow, validate pain points in prostate cancer diagnosis, identify performance requirements, and evaluate target product profile.
Outcome Ultimately, our assessment Identified that the client testing format would not fit with current urology practice patient flow and would potentially disrupt office practices. Based on this we determined that adoption of the test as currently envisioned would be low and commercial potential limited.. Additionally, we found that sensitivity and specificity of preliminary testing, while superior to existing prostate cancer diagnostics, were not robust enough for widespread adoption as a screening test. Based on these findings, client decided to return the technology to the inventor and pursue other testing platforms.
Situation An early stage biotech client was seeking partnerships to advance their lead compound and having unsuccessfully pursued partnerships for several years, the company wanted to re-evaluate opportunities for their lead asset. 3elms performed a market assessment and indication analysis to reposition the lead compound.
Solution We evaluated the mechanism of action of the lead molecule to determine potential diseases where it might have activity and performed a detailed market analysis for each potential indication, including patient segmentation and sizing, unmet needs, competitive landscape, development costs and risks, and payer acceptance. Conducting in-depth interviews with key opinion leaders to understand current treatment approaches, we validated the lead compound's mechanism of action in potential indications and test product profiles. In addition, 3elms mapped a development plan, which included trial size, end points, timelines, and estimated costs. We prioritized indications based on commercial potential and ability of the client to achieve milestones. Lastly, we highlighted key experiments to establish efficacy in priority indication and identified potential partners for high priority indication and developed partnering materials.
Outcome Based on our analyses, the client pivoted to a new indication and repositioned their lead program. With the updated market approach, the company also undertook partnering discussions and was able to secure term sheets from two potential partners (US and ex-US) for the lead program.